Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 150,700 shares, a drop of 62.8% from the December 15th total of 405,200 shares. Currently, 10.2% of the company’s stock are short sold. Based on an average daily volume of 325,900 shares, the days-to-cover ratio is presently 0.5 days.

Coeptis Therapeutics Stock Up 5.7 %

Shares of COEP traded up $0.43 on Monday, hitting $8.00. The company’s stock had a trading volume of 233,770 shares, compared to its average volume of 505,417. The firm’s fifty day moving average price is $4.33 and its 200-day moving average price is $4.33. Coeptis Therapeutics has a fifty-two week low of $2.31 and a fifty-two week high of $13.58. The company has a quick ratio of 0.40, a current ratio of 0.40 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $16.45 million, a price-to-earnings ratio of -27.59 and a beta of -1.04.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.